Last updated: July 16, 2026
ATHROMBIN-K is not a uniquely identifiable FDA/EMA drug name in the public regulatory and patent record without mapping to a specific active ingredient, strength, dosage form, and marketing authorization holder. Without that mapping, an accurate patent-exclusivity, Orange Book status, litigation, and revenue/risk analysis cannot be produced.
What is ATHROMBIN-K and what active ingredient drives the investment thesis?
A complete fundamentals and IP assessment requires the drug’s active pharmaceutical ingredient (API), formulation type, and jurisdictional registration. “ATHROMBIN-K” can refer to different products across countries and could be sold under different brand naming conventions depending on the market. Investment-grade analysis depends on the exact product definition used in the regulatory record.
Which markets list ATHROMBIN-K?
Investment scenarios differ materially by market because exclusivity is jurisdiction-specific and patent term adjustments and patent linkage are not uniform across FDA, EU, UK, and other regulators.
What is the dosage form and route?
Formulation and route drive:
- whether method-of-use or formulation patents dominate the estate
- manufacturing know-how barriers
- generic substitution risk
- tender/HTA dynamics that affect revenue durability
What is the regulatory status?
Commercial risk depends on whether the product is:
- centralized vs national authorization
- hospital vs outpatient distribution
- single-source vs multi-supplier tender frameworks
What patents protect ATHROMBIN-K and how strong is the patent estate?
A patent estate analysis requires the exact API and application family identifiers to pull:
- composition-of-matter patents
- formulation patents (process, polymorph, particle size, excipients)
- method-of-use patents (indications, dosing regimens)
- manufacturing process patents
- device/combination product patents (if applicable)
How many patents cover ATHROMBIN-K in key jurisdictions?
A defensible “patent count” and “coverage map” must tie to:
- publication numbers and family members
- assignees and ownership splits
- expiration dates by jurisdiction
- exclusivity-linkage status (Orange Book or national registers)
Which assignees own ATHROMBIN-K’s core IP?
Investment diligence requires identifying:
- originator assignees
- licensees and manufacturing partners
- challengers with parallel dossiers (generic or biosimilar-style challenges where relevant)
What is the likely expiration timeline for the core product rights?
An exclusivity timeline is actionable only when anchored to:
- earliest priority date
- patent grant/filing dates
- regulatory exclusivity type and end date (where applicable)
- patent term adjustment and supplementary protection certificate (SPC) effects (EU)
When does ATHROMBIN-K lose exclusivity and what generic entry risks exist?
Generic and competitor entry risk depends on:
- whether the product is covered by patent-listed linkage (U.S. Orange Book type linkage or equivalent)
- whether process or formulation patents block AB-rated generic substitution
- whether there are authorized generics or contract manufacturing arrangements
- whether courts have stayed or invalidated key patents
What are the likely “watch dates” for exclusivity cliff risk?
Watch dates include:
- earliest patent expiry for composition and key formulations
- regulatory exclusivity end
- last day of any pediatric exclusivity extensions (if applicable)
- any settlement “no-ATV/launch” trigger dates (if litigation exists)
What Paragraph IV or equivalent challenges affect ATHROMBIN-K?
Paragraph IV analysis requires:
- challenger ANDA filing references
- listed patent numbers challenged
- complaint filing dates
- 30-month stay impact
- settlement terms
Without a product-to-API mapping, any enumeration of challenges would be inaccurate.
What is the Orange Book status of ATHROMBIN-K?
Orange Book status must be verified by listing:
- application holder
- product code and dosage form
- active ingredient and strength
- listed patents and their expiration dates
- regulatory exclusivity (if listed)
No such mapping can be completed from the brand name alone.
What patent litigation affects ATHROMBIN-K and what settlement agreements matter?
Litigation risk is only investable when anchored to:
- case captions and court jurisdictions
- asserted patents and claims
- invalidity/unenforceability theories
- claim construction outcomes
- settlement terms with effective/trigger dates
No validated litigation record can be produced without identifying the specific marketed product and its patent listing.
How does ATHROMBIN-K compare with competing anticoagulant and thrombin-pathway products?
A competitive analysis requires:
- therapeutic class
- mechanism of action and target pathway
- dosing regimen comparability
- label indications overlap
- pricing and tender dynamics by geography
Without product identification, comparison would not be decision-grade.
What are the key differentiators that block substitution?
Differentiators typically include:
- pharmacokinetic or pharmacodynamic performance
- safety profile in specific populations
- stability and cold-chain requirements
- administration method constraints (IV/SC/oral)
- hospital formulary position
What formulations are protected by ATHROMBIN-K’s patents?
Formulation patenting is often decisive for branded sustainability, especially for:
- fixed-dose combinations
- controlled-release systems
- stability and shelf-life extensions
- bioavailability optimization
- manufacturing process improvements that prevent generic replication
A formulation patent landscape must reference:
- specific patent claims
- excluded embodiments or design-around risks
- process parameters that are enforceable or hard to replicate
What manufacturing and IP barriers exist for generic entrants targeting ATHROMBIN-K?
Entrant barriers include:
- validated manufacturing steps protected by process patents
- specifications that are hard to meet without know-how
- validated critical process parameters
- impurity profile targets enforced through patent or trade secrets
- reliance on licensed intermediates
Investment scenario: bull/base/bear outcomes for ATHROMBIN-K
A three-scenario investment view must be anchored to:
- time-to-loss of exclusivity by jurisdiction
- probability-weighted litigation outcomes
- likelihood and timing of generic entry
- pricing erosion and tender share impact
- manufacturing capacity risks and supply interruptions
No decision-grade scenario can be produced because ATHROMBIN-K cannot be mapped to a specific regulatory product record and patent family from the provided input.
Key Takeaways
- “ATHROMBIN-K” cannot be translated into an investable asset profile without mapping the brand to its exact active ingredient, strength, dosage form, and marketing authorization holder.
- Patent-expiry, Orange Book status, litigation, and generic entry risks require product-linked identifiers that are not available from the brand name alone.
- No accurate investment scenario or fundamentals assessment can be completed without those identifiers.
FAQs
- What data fields are required to map a branded drug name to an Orange Book and patent listing record?
- How do formulation patents versus method-of-use patents change generic entry timing?
- What typical settlement terms govern launch dates after patent litigation in U.S. branded-drug cases?
- How does regulatory exclusivity interact with patent term extensions (SPC, pediatric exclusivity) in EU vs U.S.?
- What indicators show whether competitors are likely to pursue an early generic launch or a later design-around?
References
No sources were cited because ATHROMBIN-K could not be uniquely identified to an active ingredient and regulatory/patent record from the provided input.
